var data={"title":"Estradiol (systemic): Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Estradiol (systemic): Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/389290?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=estradiol-systemic-drug-information\" class=\"drug drug_general\">see &quot;Estradiol (systemic): Drug information&quot;</a> and <a href=\"topic.htm?path=estradiol-systemic-patient-drug-information\" class=\"drug drug_patient\">see &quot;Estradiol (systemic): Patient drug information \t&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8018272\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Endometrial cancer: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\"> There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens. Close clinical surveillance of all women taking estrogens is important. Adding a progestin to estrogen therapy has been shown to reduce the risk of endometrial hyperplasia, which may be a precursor to endometrial cancer. Adequate diagnostic measures, including directed or random endometrial sampling when indicated, should be taken to rule out malignancy in all cases of undiagnosed persistent or recurring abnormal genital bleeding.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Cardiovascular disease:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Estrogen-alone therapy should not be used for the prevention of cardiovascular disease. The Women's Health Initiative (WHI) estrogen-alone substudy reported increased risks of stroke and deep vein thrombosis (DVT) in postmenopausal women (50 to 79 years of age) during 7.1 years of treatment with daily oral conjugated estrogens (0.625 mg) alone, relative to placebo.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\"> Estrogen plus progestin therapy should not be used for the prevention of cardiovascular disease. The WHI estrogen plus progestin substudy reported increased risks of DVT, pulmonary embolism (PE), stroke, and myocardial infarction (MI) in postmenopausal women (50 to 79 years of age) during 5.6 years of treatment with daily oral conjugated estrogens (0.625 mg) combined with medroxyprogesterone acetate (2.5 mg), relative to placebo.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Breast cancer:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">The Women's Health Initiative (WHI) estrogen plus progestin substudy demonstrated an increased risk of invasive breast cancer</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Dementia:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Estrogen-alone therapy should not be used for the prevention of dementia. The WHI Memory Study (WHIMS) estrogen-alone ancillary study of the WHI reported an increased risk of developing probable dementia in postmenopausal women 65 years and older during 5.2 years of treatment with daily conjugated estrogens (0.625 mg) alone, relative to placebo. It is unknown whether this finding applies to younger postmenopausal women.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Estrogen plus progestin therapy should not be used for the prevention of dementia. The WHIMS estrogen plus progestin ancillary study of the WHI reported an increased risk of developing probable dementia in postmenopausal women 65 years or older during 4 years of treatment with daily conjugated estrogens (0.625 mg) combined with medroxyprogesterone acetate (2.5 mg), relative to placebo. It is unknown whether this finding applies to younger postmenopausal women.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Risk vs benefits:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">In the absence of comparable data, these risks should be assumed to be similar for other doses of conjugated estrogens (with or without medroxyprogesterone acetate) and other dosage forms of estrogens (with or without progestins). Estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Secondary exposure (Evamist):</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Breast budding and breast masses in prepubertal females and gynecomastia and breast masses in prepubertal males have been reported following unintentional secondary exposure to Evamist by women using this product. In most cases, the condition resolved with removal of Evamist exposure. Women should ensure that children do not come into contact with the site(s) where Evamist is applied. Advise patients to strictly adhere to recommended instructions for use.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8018338\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Alora;</li>\n      <li>Climara;</li>\n      <li>Delestrogen;</li>\n      <li>Depo-Estradiol;</li>\n      <li>Divigel;</li>\n      <li>EC-RX Estradiol;</li>\n      <li>Elestrin;</li>\n      <li>Estrace;</li>\n      <li>Estrasorb [DSC];</li>\n      <li>Estrogel;</li>\n      <li>Evamist;</li>\n      <li>Femring;</li>\n      <li>Menostar;</li>\n      <li>Minivelle;</li>\n      <li>Vivelle-Dot</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8018339\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Climara;</li>\n      <li>Depo-Estradiol;</li>\n      <li>Divigel;</li>\n      <li>Estrace;</li>\n      <li>Estradot;</li>\n      <li>EstroGel;</li>\n      <li>Menostar;</li>\n      <li>Oesclim;</li>\n      <li>Sandoz-Estradiol Derm 100;</li>\n      <li>Sandoz-Estradiol Derm 50;</li>\n      <li>Sandoz-Estradiol Derm 75</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10824233\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Estrogen Derivative</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10824256\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=estradiol-systemic-drug-information\" class=\"drug drug_general\">see &quot;Estradiol (systemic): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Estrasorb has been discontinued in the US for more than 1 year. <b>Note:</b> Use lowest effective dose for shortest duration possible that is consistent with an individual's treatment goals and risks; all dosage needs to be adjusted based upon the patient's response. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Constitutional delay of growth and puberty (CDGP) (females):</b> Limited data available: Children &ge;12 years and Adolescents: <b>Note:</b> Begin with the lowest available dose and gradually increase. Obtain bone age every 6 months to avoid premature epiphyseal closure. If treatment continues beyond 1 year or breast growth is significant and has plateaued or breakthrough bleeding occurs, add cyclic progesterone. Continue until menstruation has been established, or longer if clinically indicated (Palmert 2012; Santos 2014; Sperling 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral (micronized, Estrace): Initial dose: 5 mcg/kg once daily; after 6 to 12 months of therapy, may increase to 10 mcg/kg once daily (Palmert 2012). Using currently available dosage forms, some have recommended starting at a fixed dose of 0.25 mg once daily (1/2 of the 0.5 mg tablet) and increasing to 0.5 mg once daily after 6 to 12 months.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Transdermal: Initial dose: 3.1 to 6.2 mcg/day patch (eg, <sup>1</sup>/<sub>8</sub> to <sup>1</sup>/<sub>4</sub> of a 25 mcg/day patch), apply at night, remove in the morning. Increase by 3.1 to 6.2 mcg/day patch every 6 months (Palmert 2012). <b>Note:</b> The practice of cutting patches to achieve low doses is cited frequently in the literature (Ankarberg-Lindgren 2001; Davenport 2010; Hindmarsh 2009; Palmert 2012); however, product specific data may not be available for all transdermal products due to product availability/manufacturing changes.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hypogonadism (females):</b> Limited data available: Children &ge;12 years and Adolescents: <b>Note:</b> Begin with the lowest available dose and gradually increase. Obtain bone age every 6 months to avoid premature epiphyseal closure. Once breast growth is significant and has plateaued or breakthrough bleeding occurs, add cyclic progesterone. Continue until menstruation has been established, or longer if clinically indicated (Palmert 2012; Sperling 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral (micronized): Initial dose: 5 mcg/kg once daily for 6 to 12 months; may then increase to 10 mcg/kg/day for 6 to 12 months; dose may be increased at every 6 to 12 month intervals by 5 mcg/kg/day, up to 20 mcg/kg/day. Do not exceed adult dose of 2 mg daily (Palmert 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Transdermal: Initial dose: 3.1 to 6.2 mcg/day patch (eg, <sup>1</sup>/<sub>8</sub> to <sup>1</sup>/<sub>4</sub> of a 25 mcg/day patch), apply at night, remove in the morning. Increase by 3.1 to 6.2 mcg/day patch every 6 months; Do not exceed adult dose of 50 to 100 mcg/24 hours (Palmert 2012).  Note: The practice of cutting patches to achieve low doses is cited frequently in the literature (Ankarberg-Lindgren 2001; Davenport 2010; Hindmarsh 2009; Palmert 2012); however, product specific data may not be available for all transdermal products due to product availability/manufacturing changes. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Turner syndrome (females):</b>  Limited data available: Children &ge;12 years and Adolescents: Begin at ~12 years of age using a low dose and gradually increase dose over 2 to 4 years to full adult dose. After 2 years of estrogen or when breakthrough bleeding occurs, add cyclic progesterone. <b>Note:</b> Full dose estrogen will be needed until at least age 30 years (Bondy 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IM: Cypionate (Depot-Estradiol): Initial: 0.2 to 0.4 mg every 4 weeks, slowly increase dose over about 2 years to the goal adult dose: 3 mg/month; one trial started at 0.2 mg/dose, then increased dose at 6 month intervals in 0.2 mg/dose increments until dose of 1 mg reached and then increased in 0.5 mg/dose increments thereafter to a final dose of 3 mg (Bondy 2007; Rosenfield 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral (micronized, Estrace): Initial dose: 5 mcg/kg once daily for the first 2 years, followed by 7.5 mcg/kg for the 3rd year, then 10 mcg/kg thereafter; once final height is attained, increase to adult dose of 1 to 2 mg/day (Bannink 2009). A fixed dose of 0.25 mg once daily; increasing to the adult dose of 2 to 4 mg/day over the course of 2 years has also been suggested (Bondy 2007). <b>Note:</b> Due to extensive first-pass metabolism, other routes of administration may be preferable. </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Topical gel (Divigel): Initial: 0.1 mg of estradiol once daily for the first year, 0.2 mg of estradiol once daily for the second year, 0.5 mg of estradiol once daily for the third year, 1 mg of estradiol once daily for the fourth year, and 1.5 mg of estradiol once daily for the fifth year. Dosing based on a trial of 23 girls that followed development for 5 years; long-term dose is unknown.  Due to lack of commercially available product for lower doses, individual sachets of 0.1 mg estradiol were prepared (Piippo 2004).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Transdermal patch: Initial: 6.25 mcg/day patch; slowly increase over about 2 years to the goal adult dose: 100 to 200 mcg/day patch (Bondy 2007)  </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <b>Note:</b> The lowest-dose commercially available patches deliver 14 and 25 &mu;g daily; preferred dose fractionation method has not been established (eg, administering a partial patch, limiting to overnight use, or administering whole patches for 7 to 10 days per month). Product specific data may not be available for splitting/cutting some transdermal patches; one center has used the following titration method using Vivelle-Dot product (Davenport 2010): </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Treatment month: </p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">0 to &lt;6 months of treatment: 3.125 mcg to 4.17 mcg/dose (equals <sup>1</sup>/<sub>8</sub> to <sup>1</sup>/<sub>6</sub> of a 25 mcg/day patch), apply at night, remove in the morning (not continuous)</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">6 to &lt;12 months of treatment: 3.125 mcg to 4.17 mcg/dose (equals <sup>1</sup>/<sub>8</sub> to <sup>1</sup>/<sub>6</sub> of a 25 mcg/day patch) apply twice weekly (continuous)</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">12 to &lt;18 months of treatment: 6.25 mcg to 8.33 mcg/dose (equals <sup>1</sup>/<sub>4</sub> to   <sup>1</sup>/<sub>3</sub> of a 25 mcg/day patch), apply twice weekly (continuous)</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">18 to &lt;24 months of treatment: 12.5 mcg/dose (equals <sup>1</sup>/<sub>2</sub> of a 25 mcg/day patch), apply twice weekly (continuous)</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">&ge;24 months of treatment: 25 mcg/day patch, apply twice weekly (continuous); then increase by one patch strength every 6 months to a final goal of 100 mcg/day continuously </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>Note:</b> See package insert for doses related to postmenopausal symptoms, prevention of osteoporosis in postmenopausal women, and palliative treatment of breast cancer or androgen-dependent prostate cancer in adults.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hypoestrogenism (female) due to hypogonadism, castration, or primary ovarian failure: </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral (Estrace): Initial: 1 to 2 mg once daily; titrate as necessary to control symptoms using minimal effective dose for maintenance therapy </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IM: Valerate (Delestrogen): 10 to 20 mg every 4 weeks </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Transdermal:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Alora: Apply 0.05 mg patch twice weekly</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Climara: Apply 0.025 mg/day patch once weekly. Adjust dose as necessary to control symptoms.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Vivelle-Dot: Apply 0.0375 mg patch twice weekly</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hypoestrogenism (female) due to hypogonadism:</b> IM: Cypionate (Depo-Estradiol): 1.5 to 2 mg once monthly</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> For most products, there are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b>  For most products, there are no dosage adjustments provided in the manufacturer's labeling (has not been studied); use is contraindicated with hepatic dysfunction or disease.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8018425\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cream, Transdermal: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">EC-RX Estradiol: 0.4% (30 g, 60 g); 0.6% (30 g, 60 g) [contains cetearyl alcohol]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Emulsion, Transdermal, as hemihydrate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Estrasorb: 4.35 mg/1.74 g (1.74 g [DSC]) [contains polysorbate 80, soybean oil]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gel, Transdermal: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Divigel: 0.25 mg/0.25 g (1 ea); 0.5 mg/0.5 g (1 ea); 1 mg/g (1 g) [contains propylene glycol, trolamine (triethanolamine)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Elestrin: 0.06% (26 g) [contains edetate disodium, propylene glycol, trolamine (triethanolamine)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Estrogel: 0.06% (50 g) [contains alcohol, usp, trolamine (triethanolamine)]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Oil, Intramuscular, as cypionate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Depo-Estradiol: 5 mg/mL (5 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Oil, Intramuscular, as valerate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Delestrogen: 10 mg/mL (5 mL) [contains chlorobutanol (chlorobutol), sesame oil]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Delestrogen: 20 mg/mL (5 mL); 40 mg/mL (5 mL) [contains benzyl alcohol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10 mg/mL (5 mL [DSC]); 20 mg/mL (5 mL); 40 mg/mL (5 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Patch Twice Weekly, Transdermal: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Alora: 0.025 mg/24 hr (1 ea, 8 ea); 0.05 mg/24 hr (1 ea, 8 ea); 0.075 mg/24 hr (1 ea, 8 ea); 0.1 mg/24 hr (1 ea, 8 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Minivelle: 0.025 mg/24 hr (8 ea); 0.0375 mg/24 hr (8 ea); 0.05 mg/24 hr (8 ea); 0.075 mg/24 hr (8 ea); 0.1 mg/24 hr (8 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Vivelle-Dot: 0.025 mg/24 hr (1 ea, 8 ea); 0.0375 mg/24 hr (1 ea, 8 ea); 0.05 mg/24 hr (1 ea, 8 ea); 0.075 mg/24 hr (1 ea, 8 ea); 0.1 mg/24 hr (1 ea, 8 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.025 mg/24 hr (8 ea); 0.0375 mg/24 hr (8 ea); 0.05 mg/24 hr (1 ea, 8 ea); 0.075 mg/24 hr (1 ea, 8 ea); 0.1 mg/24 hr (8 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Patch Weekly, Transdermal: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Climara: 0.025 mg/24 hr (4 ea); 0.0375 mg/24 hr (4 ea); 0.05 mg/24 hr (1 ea, 4 ea); 0.06 mg/24 hr (4 ea); 0.075 mg/24 hr (4 ea); 0.1 mg/24 hr (1 ea, 4 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Menostar: 14 mcg/24 hr (4 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.025 mg/24 hr (1 ea, 4 ea); 0.0375 mg/24 hr (4 ea); 0.05 mg/24 hr (1 ea, 4 ea); 0.06 mg/24 hr (4 ea); 0.075 mg/24 hr (4 ea); 0.1 mg/24 hr (1 ea, 4 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Ring, Vaginal, as acetate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Femring: 0.05 mg/24 hr (1 ea); 0.1 mg/24 hr (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Transdermal: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Evamist: 1.53 mg/spray (8.1 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Estrace: 0.5 mg, 1 mg, 2 mg [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.5 mg, 1 mg, 2 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8018341\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49280524\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span><p>(For additional information <a href=\"topic.htm?path=estradiol-systemic-drug-information\" class=\"drug drug_general\">see &quot;Estradiol (systemic): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">EC-RX Estradiol is a compounding kit. Refer to manufacturer's labeling for compounding instructions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F44524571\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;display:inline\">Estrasorb has been discontinued in the US for more than 1 year.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10824257\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: May administer with food or after a meal to reduce GI upset</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral: Injection for IM use only</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cypionate: Inspect for any particulate (particularly crystals); warming and shaking the vial should redissolve any crystals</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Valerate: Should be injected into the upper outer quadrant of the gluteal muscle; administer with a dry needle (solution may become cloudy with wet needle).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Transdermal: <b>Note:</b> See package insert for administration related to postmenopausal symptoms, prevention of osteoporosis in postmenopausal women, and palliative treatment of breast cancer or androgen-dependent prostate cancer in adults. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gel (Divigel): Apply to clean, dry, unbroken skin at the same time each day. Apply entire contents of packet to right or left upper thigh each day (alternate sites). Do not apply to face, breasts, vaginal area, or irritated skin. Apply over an area ~5x7 inches. Do not wash application site for 1 hour. Allow to dry for 5 minutes prior to dressing. Gel is flammable; avoid fire or flame until dry. After application, wash hands with soap and water. Prior to the first use, pump must be primed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Transdermal patch: Do not apply transdermal system to breasts, but place on trunk of body (preferably abdomen). Rotate application sites allowing a 1-week interval between applications at a particular site. Do not apply to oily, damaged or irritated skin; avoid waistline or other areas where tight clothing may rub the patch off. Apply patch immediately after removing from protective pouch. In general, if patch falls off, the same patch may be reapplied or a new system may be used for the remainder of the dosing interval (not recommended with all products) When replacing patch, reapply to a new site. Swimming, bathing, or showering are not expected to affect use of the patch. Note the following exceptions: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Climara, Menostar, Minivelle: Swimming, bathing, or wearing patch while in a sauna have not been studied; adhesion of patch may be decreased or delivery of estradiol may be affected. Showering is not expected to cause the Minivelle patch to fall off. Remove patch slowly after use to avoid skin irritation. If any adhesive remains on the skin after removal, first allow skin to dry for 15 minutes, then gently rub area with an oil-based cream or lotion. If patch falls off, a new patch should be applied for the remainder of the dosing interval. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49132514\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 2]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends single gloving for administration of intact tablets or capsules. For IM preparation, NIOSH recommends double gloving, a protective gown, and ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator). Double gloving and a gown are required during IM administration. NIOSH recommends double gloving, a protective gown, and (if liquid that could splash) eye/face protection for administration of a topical product; if there is potential for inhalation, respiratory protection is recommended (NIOSH 2016). Assess risk to determine appropriate containment strategy (USP-NF 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12764945\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Store all products at controlled room temperature. In addition:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Depo-Estradiol: Protect from light.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Evamist: Do not freeze.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Femring: Store in pouch.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Transdermal patch (all products): Store in protective pouch.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Climara, Menostar: Do not store &gt;30&deg;C (&gt;86&deg;F).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10824238\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of hypoestrogenism due to hypogonadism, castration, or primary ovarian failure; treatment of moderate to severe vasomotor symptoms of menopause, moderate to severe symptoms of vulvar and vaginal atrophy due to menopause, palliative treatment of breast cancer in select patients, palliative treatment of androgen-dependent prostate cancer, and prevention of osteoporosis in postmenopausal women (All indications: FDA approved in adults); has also been used for management of Turner Syndrome and for induction of puberty in patients with delayed puberty </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8018336\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Alora may be confused with Aldara</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Elestrin may be confused with alosetron</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Geriatric Patients: High-Risk Medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Beers Criteria: Estrogens (oral or topical patch products only), with or without progestins, are identified in the Beers Criteria as potentially inappropriate medications to be avoided in patients 65 years and older (independent of diagnosis or condition) due to their carcinogenic potential (breast and endometrium) and lack of cardioprotection or cognitive protection in older women. Low-dose intravaginal estrogen (vaginal creams or tablets) are <i>acceptable</i> for dyspareunia, lower urinary tract infections, and other vaginal symptoms. Of note, women with a history of breast cancer not responding to non-hormonal therapies are advised to discuss the risks/benefits of low dose vaginal estrogen (estradiol less than 25 mcg twice weekly) with their health care provider (Beers Criteria [AGS 2015]).</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Pharmacy Quality Alliance (PQA): Estrogens (oral and topical patch products only), with or without progestins, are identified as a high-risk medication in patients 65 years and older on the PQA&rsquo;s Use of High-Risk Medications in the Elderly (HRM) performance measure, a safety measure used by the Centers for Medicare and Medicaid Services (CMS) for Medicare plans.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Transdermal patch may contain conducting metal (eg, aluminum); remove patch prior to MRI.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Vivelle: Brand name for estradiol [US and multiple international markets, but also the brand name for ethinyl estradiol and norgestimate [Austria]</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8018353\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Some adverse reactions observed with estrogen and/or progestin combination therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cardiovascular: Cerebrovascular accident, deep vein thrombosis, edema, hypertension, local thrombophlebitis, myocardial infarction, pulmonary thromboembolism, retinal thrombosis, thrombophlebitis, venous thromboembolism </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Anxiety, chorea, dementia, depression, dizziness, exacerbation of epilepsy, headache, hypoesthesia, irritability, migraine, mood disorder, nervousness, nipple pain, pain</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatologic: Chloasma, erythema multiforme, erythema nodosum, localized erythema (transdermal patch), loss of scalp hair, pruritus, skin discoloration (melasma), skin rash, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Endocrine &amp; metabolic: Change in libido, change in menstrual flow (alterations in frequency and flow of bleeding patterns), exacerbation of diabetes mellitus, exacerbation of porphyria, fibrocystic breast changes, fluid retention, galactorrhea, hirsutism, hot flash, hypocalcemia, increased serum triglycerides, weight gain, weight loss</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Abdominal cramps, abdominal pain, bloating, carbohydrate intolerance, constipation, diarrhea, dyspepsia, flatulence, gallbladder disease, gastroenteritis, nausea, pancreatitis, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Genitourinary: Abnormal uterine bleeding, breakthrough bleeding, breast hypertrophy, breast tenderness, cervical polyp, change in cervical ectropion, change in cervical secretions, dysmenorrhea, endometrial hyperplasia, endometrium disease, leukorrhea, mastalgia, nipple discharge, spotting, urinary tract infection, uterine fibroids (size increased), uterine pain, vaginal discomfort (vaginal ring; burning, irritation, itching), vaginal hemorrhage, vaginitis, vulvovaginal candidiasis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hematologic &amp; oncologic: Hemorrhagic eruption, hypercoagulability state, malignant neoplasm of breast, ovarian cancer</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hepatic: Cholestatic jaundice, exacerbation of hepatic hemangioma</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hypersensitivity: Anaphylactoid reaction, anaphylaxis, angioedema, hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Infection: Fungal infection, infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Local: Application site reaction (gel, spray, transdermal patch)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Neuromuscular &amp; skeletal: Arthralgia, arthropathy, back pain, exacerbation of systemic lupus erythematosus, leg cramps, limb pain, myalgia, neck pain, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Ophthalmic: Change in corneal curvature (steepening), conjunctivitis, contact lens intolerance</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Otic: Otitis media</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Respiratory: asthma, bronchitis, cough, exacerbation of asthma, flu-like symptoms, nasopharyngitis, pharyngitis, rhinitis, sinus congestion, sinus headache, sinusitis, upper respiratory tract infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Miscellaneous: Accidental injury, cyst</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">Rare but important or life-threatening: Bowel obstruction (vaginal ring), genitourinary complaint (inadvertent ring insertion into the bladder should be considered with unexplained urinary complaints), hemorrhage, mechanical complication of genitourinary device (ring adherence to vaginal or bladder wall), portal vein thrombosis, toxic shock syndrome (vaginal ring), unstable angina pectoris</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8018348\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Angioedema, anaphylactic reaction, or hypersensitivity to estradiol or any component of the formulation; undiagnosed abnormal genital bleeding; DVT or PE (current or history of); active or history of arterial thromboembolic disease (eg, stroke, MI); breast cancer (known, suspected or history of), except in appropriately selected patients being treated for metastatic disease; estrogen-dependent tumor (known or suspected); hepatic impairment or disease; known protein C, protein S, antithrombin deficiency or other known thrombophilic disorders; pregnancy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Documentation of allergenic cross-reactivity for estrogens is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): <b>Note:</b> May be dosage form dependent (consult product labeling): Breastfeeding; endometrial hyperplasia; active thrombophlebitis; partial or complete loss of vision or diplopia due to ophthalmic vascular disease; presence or history of hepatic tumors (benign or malignant); porphyria; classical migraine.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8018349\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anaphylaxis: Anaphylaxis requiring emergency medical management has been reported and may develop at any time during therapy. Angioedema involving the face, feet, hands, larynx, and tongue has also been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Breast cancer: <b>[US Boxed Warning]: Based on data from the Women&rsquo;s Health Initiative (WHI) studies, an increased risk of invasive breast cancer was observed in postmenopausal women using conjugated estrogens (CE) in combination with medroxyprogesterone acetate (MPA).</b> This risk may be associated with duration of use and declines once combined therapy is discontinued (Chlebowski 2009). The risk of invasive breast cancer was decreased in postmenopausal women with a hysterectomy using CE only, regardless of weight. However, the risk was not significantly decreased in women at high risk for breast cancer (family history of breast cancer, personal history of benign breast disease) (Anderson 2012). An increase in abnormal mammogram findings has also been reported with estrogen alone or in combination with progestin therapy. Estrogen use may lead to severe hypercalcemia in patients with breast cancer and bone metastases; discontinue estrogen if hypercalcemia occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Dementia: <b>[US Boxed Warning]: Estrogens with or without progestin should not be used to prevent dementia. In the Women&rsquo;s Health Initiative Memory Study (WHIMS), an increased incidence of probable dementia was observed in women &ge;65 years of age taking CE alone or in combination with MPA.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Endometrial cancer: <b>[US Boxed Warning]: The use of unopposed estrogen in women with a uterus is associated with an increased risk of endometrial cancer. The addition of a progestin to estrogen therapy may decrease the risk of endometrial hyperplasia, a precursor to endometrial cancer. Adequate diagnostic measures, including endometrial sampling if indicated, should be performed to rule out malignancy in postmenopausal women with undiagnosed abnormal vaginal bleeding.</b> There is no evidence that the use of natural estrogens results in a different endometrial risk profile than synthetic estrogens at equivalent estrogen doses. The risk of endometrial cancer is dose and duration dependent; risk appears to be greatest with use &ge;5 years and may persist following discontinuation of therapy. The use of a progestin is not generally required when low doses of estrogen are used locally for vaginal atrophy (NAMS 2012; NAMS 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Endometriosis: Estrogens may exacerbate endometriosis. Malignant transformation of residual endometrial implants has been reported posthysterectomy with unopposed estrogen therapy. Consider adding a progestin in women with residual endometriosis posthysterectomy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Inherited thrombophilia: Women with inherited thrombophilias (eg, protein C or S deficiency) may have increased risk of venous thromboembolism (DeSancho 2010; van Vlijmen 2011). Use is contraindicated in women with protein C, protein S, antithrombin deficiency, or other known thrombophilic disorders.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Lipid effects: Estrogen compounds are generally associated with lipid effects such as increased HDL-cholesterol and decreased LDL-cholesterol. Triglycerides may also be increased in women with preexisting hypertriglyceridemia; discontinue if pancreatitis occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Ovarian cancer: Postmenopausal estrogens with or without progestins may increase the risk of ovarian cancer; however, the absolute risk to an individual woman is small. Although results from various studies are not consistent, risk does not appear to be significantly associated with the duration, route, or dose of therapy. In one study, the risk decreased after 2 years following discontinuation of therapy (M&oslash;rch 2009). Although the risk of ovarian cancer is rare, women who are at an increased risk (eg, family history) should be counseled about the association (NAMS 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Retinal vascular thrombosis: Estrogens may cause retinal vascular thrombosis; discontinue if migraine, loss of vision, proptosis, diplopia, or other visual disturbances occur; discontinue permanently if papilledema or retinal vascular lesions are observed on examination.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Asthma: Use caution with asthma; may exacerbate disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Carbohydrate intolerance: May have adverse effects on glucose tolerance; use caution in women with diabetes.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Cardiovascular disease:<b>[US Boxed Warning]: Estrogens with or without progestin should not be used to prevent cardiovascular disease. Using data from the Women&rsquo;s Health Initiative (WHI) studies, an increased risk of deep vein thrombosis (DVT) and stroke has been reported with CE and an increased risk of DVT, stroke, pulmonary emboli (PE) and myocardial infarction (MI) has been reported with CE with MPA in postmenopausal women 50 to 79 years of age.</b> Additional risk factors include diabetes mellitus, hypercholesterolemia, hypertension, SLE, obesity, tobacco use, and/or history of venous thromboembolism (VTE). Risk factors should be managed appropriately; discontinue use if adverse cardiovascular events occur or are suspected. Use is contraindicated in women with active DVT, PE, active arterial thromboembolic disease or a history of these conditions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Diseases exacerbated by fluid retention: Use caution with diseases which may be exacerbated by fluid retention, including cardiac or renal dysfunction.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Epilepsy: Use caution with epilepsy; may exacerbate disease. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Gallbladder disease: Use of postmenopausal estrogen may be associated with an increased risk of gallbladder disease requiring surgery.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic dysfunction: Estrogens are poorly metabolized in patients with hepatic dysfunction. Use caution with a history of cholestatic jaundice associated with prior estrogen use or pregnancy. Discontinue if jaundice develops or if acute or chronic hepatic disturbances occur. Use is contraindicated with hepatic impairment or disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic hemangiomas: Use caution with hepatic hemangiomas; may exacerbate disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hereditary angioedema: Exogenous estrogens may exacerbate angioedema symptoms in women with hereditary angioedema.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypoparathyroidism: Use caution with hypoparathyroidism; estrogen-induced hypocalcemia may occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Migraine: Use caution with migraine; may exacerbate disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Porphyria: Use caution with porphyria; may exacerbate disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; SLE: Use caution with SLE; may exacerbate disease. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Thyroid replacement therapy: Estrogens may increase thyroid-binding globulin (TBG) levels leading to increased circulating total thyroid hormone levels. Women on thyroid replacement therapy may require higher doses of thyroid hormone while receiving estrogens.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Pediatric: Prior to puberty, estrogens may cause premature closure of the epiphyses. Premature breast development, vaginal bleeding, and vaginal cornification may be induced in girls. Modification of the normal puberty process may occur in boys.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Surgical patients: Whenever possible, estrogens should be discontinued at least 4 to 6 weeks prior to elective surgery associated with an increased risk of thromboembolism or during periods of prolonged immobilization. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Chlorobutanol: Some products may contain chlorobutanol (a chloral derivative) as a preservative, which may be habit forming.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Tartrazine: Some products may contain tartrazine.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Topical emulsion, gel: Absorption of the topical emulsion (Estrasorb) and topical gel (Elestrin) is increased by application of sunscreen; do not apply sunscreen within close proximity of estradiol. Application of sunscreen or lotion after EstroGel decreases absorption of estradiol; the effect of applying sunscreen or lotion prior to Estrogel has not been studied. Application of Divigel with sunscreen has not been evaluated. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Topical spray: When sunscreen is applied ~1 hour prior to the topical spray (Evamist), no change in absorption was observed (estradiol absorption was decreased when sunscreen is applied 1 hour after Evamist).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Transdermal patch: May contain conducting metal (eg, aluminum); remove patch prior to MRI.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Vaginal ring: Use may not be appropriate in women with narrow vagina, vaginal stenosis, vaginal infections, cervical prolapse, rectoceles, cystoceles, or other conditions which may increase the risk of vaginal irritation, ulceration, or increase the risk of expulsion. Ring should be removed in case of ulceration, erosion, or adherence to vaginal wall; do not reinsert until healing is complete. Ensure proper vaginal placement of the ring to avoid inadvertent urinary bladder insertion.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Laboratory changes: The use of estrogens and/or progestins may change the results of some laboratory tests (eg, coagulation factors, lipids, glucose tolerance, binding proteins). The dose, route, and the specific estrogen/progestin influence these changes. In addition, personal risk factors (eg, cardiovascular disease, smoking, diabetes, age) also contribute to adverse events; use of specific products may be contraindicated in women with certain risk factors.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Osteoporosis use: For use only in women at significant risk of osteoporosis and for who other nonestrogen medications are not considered appropriate.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Risks vs benefits: <b>[US Boxed Warning]: Estrogens with or without progestin should be used for the shortest duration possible at the lowest effective dose consistent with treatment goals and risks for the individual woman.</b> Patients should be reevaluated as clinically appropriate to determine if treatment is still necessary. Available data related to treatment risks are from Women&rsquo;s Health Initiative (WHI) studies, which evaluated oral CE 0.625 mg with or without MPA 2.5 mg relative to placebo in postmenopausal women. Other combinations and dosage forms of estrogens and progestins were not studied. <b>Outcomes reported from clinical trials using CE with or without MPA should be assumed to be similar for other doses and other dosage forms of estrogens and progestins until comparable data becomes available.</b> Women who are early in menopause, who are in good cardiovascular health, and who are at low risk for adverse cardiovascular events can be considered candidates for estrogen with or without progestin therapy for the relief of menopausal symptoms (ACOG 565 2013). Use of a transdermal product should be considered over an oral agent in women requiring systemic therapy who have risk factors for venous thromboembolism or coronary heart disease (ACOG 556 2013; Schenck-Gustafsson 2011; Tremollieres 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Secondary exposure: Estradiol may be transferred to another person following skin-to-skin contact with the application site. <b>[US Boxed Warning]: Breast budding and breast masses in prepubertal females and gynecomastia and breast masses in prepubertal males have been reported following unintentional contact with application sites of women using topical estradiol (Evamist). Patients should strictly adhere to instructions for use in order to prevent secondary exposure. In most cases, conditions resolved with removal of estradiol exposure.</b> If unexpected changes in sexual development occur in prepubertal children, the possibility of unintentional estradiol exposure should be evaluated by a health care provider. Discontinue if conditions for the safe use of the topical spray cannot be met.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Vulvar and vaginal atrophy use: Moderate-to-severe symptoms of vulvar and vaginal atrophy include vaginal dryness, dyspareunia, and atrophic vaginitis. When used solely for the treatment of vulvar and vaginal atrophy, topical vaginal products should be considered. Use caution applying topical products to severely atrophic vaginal mucosa. Use of a progestin is normally not required when low-dose estrogen is applied locally and only for this purpose (NAMS 2012; NAMS 2013).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26535327\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Some dosage forms may contain propylene glycol; in neonates large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP, 1997; Shehab, 2009).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8018356\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP1A2 (major), CYP2A6 (minor), CYP2B6 (minor), CYP2C19 (minor), CYP2C9 (minor), CYP2D6 (minor), CYP2E1 (minor), CYP3A4 (major), P-glycoprotein/ABCB1; <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP1A2 (weak)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8018357\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=15980&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Ajmaline: Estrogen Derivatives may enhance the adverse/toxic effect of Ajmaline. Specifically, the risk for cholestasis may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anastrozole: Estrogen Derivatives may diminish the therapeutic effect of Anastrozole. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anthrax Immune Globulin (Human): Estrogen Derivatives may enhance the thrombogenic effect of Anthrax Immune Globulin (Human). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anticoagulants: Estrogen Derivatives may diminish the anticoagulant effect of Anticoagulants. More specifically, the potential prothrombotic effects of some estrogens and progestin-estrogen combinations may counteract anticoagulant effects.  Management: Carefully weigh the prospective benefits of estrogens against the potential increased risk of procoagulant effects and thromboembolism.  Use is considered contraindicated under some circumstances. Refer to related guidelines for specific recommendations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ascorbic Acid: May increase the serum concentration of Estrogen Derivatives.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">C1 inhibitors: Estrogen Derivatives may enhance the thrombogenic effect of C1 inhibitors. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabis: May decrease the serum concentration of CYP1A2 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chenodiol: Estrogen Derivatives may diminish the therapeutic effect of Chenodiol.  Management: Monitor clinical response to chenodiol closely when used together with any estrogen derivative.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: CYP1A2 Inhibitors (Weak) may increase the serum concentration of CloZAPine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticosteroids (Systemic): Estrogen Derivatives may increase the serum concentration of Corticosteroids (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP1A2 Inducers (Moderate): May decrease the serum concentration of CYP1A2 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Moderate): May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Estrogen Derivatives.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Estrogen Derivatives.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cyproterone: May decrease the serum concentration of CYP1A2 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP3A4 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dantrolene: Estrogen Derivatives may enhance the hepatotoxic effect of Dantrolene. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dehydroepiandrosterone: May enhance the adverse/toxic effect of Estrogen Derivatives.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Enzalutamide: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Concurrent use of enzalutamide with CYP3A4 substrates that have a narrow therapeutic index should be avoided.  Use of enzalutamide and any other CYP3A4 substrate should be performed with caution and close monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Exemestane: Estrogen Derivatives may diminish the therapeutic effect of Exemestane. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hemin: Estrogen Derivatives may diminish the therapeutic effect of Hemin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Estrogenic Properties): May enhance the adverse/toxic effect of Estrogen Derivatives.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hyaluronidase: Estrogen Derivatives may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving estrogens (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immune Globulin: Estrogen Derivatives may enhance the thrombogenic effect of Immune Globulin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Indium 111 Capromab Pendetide: Estrogen Derivatives may diminish the diagnostic effect of Indium 111 Capromab Pendetide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">LamoTRIgine: Estrogen Derivatives may decrease the serum concentration of LamoTRIgine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lenalidomide: Estrogen Derivatives may enhance the thrombogenic effect of Lenalidomide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mitotane: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Doses of CYP3A4 substrates may need to be adjusted substantially when used in patients being treated with mitotane.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mivacurium: Estrogen Derivatives may increase the serum concentration of Mivacurium. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective): May enhance the thrombogenic effect of Estrogen Derivatives. Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective) may increase the serum concentration of Estrogen Derivatives.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ospemifene: Estrogen Derivatives may enhance the adverse/toxic effect of Ospemifene. Estrogen Derivatives may diminish the therapeutic effect of Ospemifene. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pitolisant: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Combined use of pitolisant with a CYP3A4 substrate that has a narrow therapeutic index should be avoided. Other CYP3A4 substrates should be monitored more closely when used with pitolisant.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pomalidomide: May enhance the thrombogenic effect of Estrogen Derivatives. Management: Canadian pomalidomide labeling recommends caution with use of hormone replacement therapy and states that hormonal contraceptives are not recommended. US pomalidomide labeling does not contain these specific recommendations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ranolazine: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ROPINIRole: Estrogen Derivatives may increase the serum concentration of ROPINIRole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sarilumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Siltuximab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Somatropin: Estrogen Derivatives may diminish the therapeutic effect of Somatropin. Shown to be a concern with oral hormone replacement therapy in postmenopausal women.  Management: Monitor for reduced growth hormone efficacy. A larger somatropin dose may be required to reach treatment goal.  This interaction does not appear to apply to non-orally administered estrogens (e.g., transdermal, vaginal ring).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">St John's Wort: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Succinylcholine: Estrogen Derivatives may increase the serum concentration of Succinylcholine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Teriflunomide: May decrease the serum concentration of CYP1A2 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thalidomide: Estrogen Derivatives may enhance the thrombogenic effect of Thalidomide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Theophylline Derivatives: Estrogen Derivatives may increase the serum concentration of Theophylline Derivatives. <b> Exceptions: </b>Dyphylline.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thyroid Products: Estrogen Derivatives may diminish the therapeutic effect of Thyroid Products. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tipranavir: Estrogen Derivatives may enhance the dermatologic adverse effect of Tipranavir. The combination of tipranavir/ritonavir and ethinyl estradiol/norethindrone was associated with a high incidence of skin rash. Tipranavir may decrease the serum concentration of Estrogen Derivatives.  Management: Women using hormonal contraceptives should consider alternative, non-hormonal forms of contraception.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">TiZANidine: CYP1A2 Inhibitors (Weak) may increase the serum concentration of TiZANidine.  Management: Avoid these combinations when possible.  If combined use is necessary, initiate tizanidine at an adult dose of 2 mg and increase in 2 to 4 mg increments based on patient response. Monitor for increased effects of tizanidine, including adverse reactions.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ursodiol: Estrogen Derivatives may diminish the therapeutic effect of Ursodiol. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8018361\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Folic acid absorption may be decreased. Routine use of ethanol increases estrogen level and risk of breast cancer; may also increase the risk of osteoporosis. Management: Avoid ethanol.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8018343\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">X (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8018344\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">In general, the use of estrogen and progestin as in combination hormonal contraceptives has not been associated with teratogenic effects when inadvertently taken early in pregnancy. These products are contraindicated for use during pregnancy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10824261\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Blood pressure, weight, height, serum calcium, glucose, liver enzymes; bone maturation and epiphyseal effects in young patients in whom bone growth is not complete; breast exam, mammogram, Papanicolaou smear, signs for endometrial cancer in female patients with a uterus; bone density measurement if used for prevention of osteoporosis</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Turner Syndrome and CDPG (puberty induction): Adolescents: Signs of puberty progression, ovarian tissue growth/changes (pelvic ultrasound), height, weight, growth parameters, breast exam, mammogram, Papanicolaou smear (Sperling 2014)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27119868\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric patients (Janfaza 2006):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Tanner stage 1: Females: 5.9 &plusmn; 9.7 pmol/L, Males: 1.5 &plusmn; 4.1</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Tanner stage 2: Females: 25.3 &plusmn; 4.0 pmol/L, Males: 2.6 &plusmn; 3.0</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Tanner stage 3: Females: 84.1 &plusmn; 120.5 pmol/L, Males: 8.7 &plusmn; 11.0</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Tanner stage 4: Females: 97.3 &plusmn; 137.7 pmol/L, Males: 13.0 &plusmn; 9.4</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Tanner stage 5: Females: 174.3 &plusmn; 239.5 pmol/L, Males: 15.5 &plusmn; 9.4</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adults: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Females: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Premenopausal: 30 to 400 pg/mL (SI: 110 to 1,468 pmol/L) (depending on phase of menstrual cycle)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Postmenopausal: 0 to 30 pg/mL (SI: 0 to 110 pmol/L)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adult males: 10 to 50 pg/mL (SI: 37 to 184 pmol/L) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8018378\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Estrogens are responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics. Estradiol is the principle intracellular human estrogen and is more potent than estrone and estriol at the receptor level; it is the primary estrogen secreted prior to menopause. Following menopause, estrone and estrone sulfate are more highly produced. Estrogens modulate the pituitary secretion of gonadotropins, luteinizing hormone, and follicle-stimulating hormone through a negative feedback system; estrogen replacement reduces elevated levels of these hormones in postmenopausal women.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8018385\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Well absorbed from the gastrointestinal tract, mucous membranes, and the skin. Average serum estradiol concentrations (C<sub>avg</sub>) vary by product</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Injection: Estradiol valerate and estradiol cypionate are absorbed over several weeks following IM injection</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Topical: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Alora: C<sub>avg</sub>: 41 to 98 pg/mL</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Climara: C<sub>avg</sub>: 22 to 106 pg/mL</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Divigel: C<sub>avg</sub>: 9.8 to 30.5 pg/mL</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Elestrin: C<sub>avg</sub>: 15.4 to 39.2 pg/mL; Exposure increased by 55% with application of sunscreen 10 minutes prior to dose </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Estrasorb: Mean serum concentration on day 22 of therapy: ~35 to 65 pg/mL; Exposure increased by ~38% with application of sunscreen 10 minutes prior to estradiol 8.7 mg and exposure increased by ~46% when sunscreen was applied 25 minutes after estradiol application.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Estrogel: C<sub>avg</sub> on day 14 of therapy: 28.3 pg/mL. C<sub>max</sub> of estradiol is altered by repeated daily application (for 7 days) of sunscreen (decreased by 16%) or lotion (increased by 73%) when applied 1 hour after the dose.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Evamist: C<sub>avg</sub>: 19.6 to 30.9 pg/mL</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Menostar: C<sub>avg</sub>: 13.7 pg/mL</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Vivelle-Dot: C<sub>avg</sub>: 34 to 104 pg/mL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Vaginal: Femring: Rapid during the first hour following application, then declines to a steady rate over 3 months; C<sub>avg</sub>: 40.6 to 76 pg/mL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Widely distributed; high concentrations in the sex hormone target organs</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: Bound to sex hormone-binding globulin and albumin </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic; partial metabolism via CYP3A4 enzymes; estradiol is reversibly converted to estrone and estriol; oral estradiol also undergoes enterohepatic recirculation by conjugation in the liver, followed by excretion of sulfate and glucuronide conjugates into the bile, then hydrolysis in the intestine and estrogen reabsorption. Sulfate conjugates are the primary form found in postmenopausal women. With transdermal application, less estradiol is metabolized leading to higher circulating concentrations of estradiol and lower concentrations of estrone and conjugates.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Primarily urine (as estradiol, estrone, estriol and their glucuronide and sulfate conjugates) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8018427\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Gel</b> (Divigel Transdermal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.25 mg/0.25gm (1): $4.95</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5 mg/0.5 g (1): $4.95</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg/g (1 g): $4.95</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Gel</b> (Elestrin Transdermal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.52 MG/0.87 GM (0.06%) (26 g): $115.96</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Gel</b> (Estrogel Transdermal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.75 MG/1.25 GM (0.06%) (50 g): $145.61</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Oil</b> (Delestrogen Intramuscular)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg/mL (5 mL): $159.28</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg/mL (5 mL): $224.48</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg/mL (5 mL): $372.37</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Oil</b> (Depo-Estradiol Intramuscular)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg/mL (5 mL): $126.35</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Oil</b> (Estradiol Valerate Intramuscular)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg/mL (5 mL): $144.31</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg/mL (5 mL): $239.38</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Patch weekly</b> (Climara Transdermal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.025 mg/24 hrs (4): $150.64</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.0375 mg/24 hrs (4): $150.64</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.05 mg/24 hrs (1): $37.66</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.06 mg/24 hrs (4): $150.64</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.075 mg/24 hrs (4): $150.64</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.1 mg/24 hrs (1): $37.66</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Patch weekly</b> (Estradiol Transdermal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.025 mg/24 hrs (4): $88.40</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.0375 mg/24 hrs (4): $88.40</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.05 mg/24 hrs (4): $88.40</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.06 mg/24 hrs (4): $88.40</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.075 mg/24 hrs (4): $88.40</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.1 mg/24 hrs (4): $88.40</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Patch weekly</b> (Menostar Transdermal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">14 mcg/24 hrs (4): $194.72</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Patch, twice-weekly</b> (Alora Transdermal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.025 mg/24 hrs (1): $15.48</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.05 mg/24 hrs (1): $16.94</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.075 mg/24 hrs (1): $17.29</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.1 mg/24 hrs (1): $17.69</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Patch, twice-weekly</b> (Estradiol Transdermal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.025 mg/24 hrs (8): $90.62</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.0375 mg/24 hrs (8): $90.63</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.05 mg/24 hrs (8): $90.69</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.075 mg/24 hrs (8): $108.91</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.1 mg/24 hrs (8): $90.83</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Patch, twice-weekly</b> (Minivelle Transdermal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.025 mg/24 hrs (8): $198.05</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.0375 mg/24 hrs (8): $198.05</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.05 mg/24 hrs (8): $198.05</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.075 mg/24 hrs (8): $198.05</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.1 mg/24 hrs (8): $198.05</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Patch, twice-weekly</b> (Vivelle-Dot Transdermal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.025 mg/24 hrs (8): $145.49</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.0375 mg/24 hrs (8): $145.50</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.05 mg/24 hrs (8): $145.61</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.075 mg/24 hrs (8): $145.76</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.1 mg/24 hrs (8): $145.81</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Ring</b> (Femring Vaginal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.05 mg/24 hrs (1): $532.40</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.1 mg/24 hrs (1): $567.35</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Evamist Transdermal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1.53 mg/spray (8.1 mL): $141.45</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Estrace Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5 mg (100): $623.57</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg (100): $623.57</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg (100): $800.41</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Estradiol Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5 mg (100): $55.12</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg (100): $68.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg (100): $94.15</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11390228\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Aerodiol (AT, BE);</li>\n      <li>Bedol (GB, IE);</li>\n      <li>Climaderm (BR, VE);</li>\n      <li>Climara (AT, AU, BB, BE, BG, CH, CZ, EE, FI, FR, IE, KR, LU, LV, NZ, PH, PL, RU, TH, ZA);</li>\n      <li>Dermestril (BE, CZ, DE, FI, IT, PT);</li>\n      <li>Dermestril Septem (FR);</li>\n      <li>Divigel (CH, DK, EE, IN, LV, MY, SE, SG, TH, TW);</li>\n      <li>Enadiol (CL, PY);</li>\n      <li>Estra Gel (TW);</li>\n      <li>Estrade (TW);</li>\n      <li>Estraderm (CO, DK, ES, SE, VN);</li>\n      <li>Estraderm MX (AU, IN, PT, SA, SG);</li>\n      <li>Estraderm TTS (AE, AT, BF, BH, BJ, CI, CO, CY, CZ, DE, EG, ET, FR, GB, GH, GM, GN, GR, IL, IQ, IR, IT, JO, KE, KR, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, NZ, OM, PL, PY, QA, SC, SD, SL, SN, SY, TN, TR, TZ, UG, YE, ZA, ZM);</li>\n      <li>Estradiol Depot (KR);</li>\n      <li>Estradot (AU, BR, CZ, DE, ES, FI, GB, GR, IE, NO, PT, SE, UY);</li>\n      <li>Estramon (UA);</li>\n      <li>Estrapatch (FR);</li>\n      <li>Estreva (DE, HK, PE, PT, TR, VN);</li>\n      <li>Estreva Gel (PE);</li>\n      <li>Estrifam (DE);</li>\n      <li>Estro-Pause (ZA);</li>\n      <li>Estrofem (AR, AT, AU, BE, BH, BR, CH, CN, CZ, DK, EE, FI, FR, HK, HU, IL, IN, IS, JO, KR, KW, LB, LT, LU, LV, NZ, PH, RU, SA, SG, SI, TH, UY);</li>\n      <li>Estrofem Forte (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Estrogel (VE);</li>\n      <li>Estrozhel (UA);</li>\n      <li>Evopad (ES);</li>\n      <li>Evorel (AR, BB, BM, BS, DK, GY, IE, IL, JM, NL, NO, PR, SE, SR, TT, UY, ZA);</li>\n      <li>Evorel Conti (BB, BM, BS, GY, JM, NL, PR, SR, TT);</li>\n      <li>Fem (CN);</li>\n      <li>Femanest (SE);</li>\n      <li>Fematab (IE);</li>\n      <li>Fematrix (GB, IE);</li>\n      <li>Feminova (BE);</li>\n      <li>Femsept (FR);</li>\n      <li>Femseven (GB, IE);</li>\n      <li>Femtran (AU, NZ);</li>\n      <li>Ginoderm Gel (PY);</li>\n      <li>Gynokadin (DE);</li>\n      <li>Gynova (BD);</li>\n      <li>GynPolar (DE);</li>\n      <li>Kliovance (AU);</li>\n      <li>Lindisc (AR, CO, CR, EC, GT, HN, NI, PA, SV);</li>\n      <li>Linoladiol N (EE);</li>\n      <li>Lumelin 2 (TW);</li>\n      <li>Menodin-Retard (CO);</li>\n      <li>Menorest (AU, DE, IT);</li>\n      <li>Merimono (DE);</li>\n      <li>Oesclim (FR);</li>\n      <li>Oestrodose (IL);</li>\n      <li>Postmenop (TH);</li>\n      <li>Preda (KR);</li>\n      <li>Primogyn Depot (ZA);</li>\n      <li>Progyluton 21 (ZW);</li>\n      <li>Progynon (CH, DE, DK, IT, SE);</li>\n      <li>Progynon Depot (IN, TW);</li>\n      <li>Progynova (AR, AT, AU, BE, BZ, CL, CN, CO, CR, DO, ES, FI, FR, GT, HN, ID, IL, IN, KR, LK, MT, MY, NI, NZ, PA, PE, PH, PL, RU, SE, SG, SV, UY, VE, ZA);</li>\n      <li>Prohinova (UA);</li>\n      <li>Prosu 2 (TW);</li>\n      <li>Provames (FR);</li>\n      <li>Pyvihel (UA);</li>\n      <li>Sandrena (BR, CH);</li>\n      <li>Sandrena Gel (AU, DE);</li>\n      <li>Sisare Gel (DE);</li>\n      <li>Thais (FR);</li>\n      <li>Tradelia (DE);</li>\n      <li>Valiera (VN);</li>\n      <li>Vivelle-Dot (BE, DK);</li>\n      <li>Vivelledot (FR);</li>\n      <li>Zumenon (AT, BE, GB)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/estradiol-systemic-pediatric-drug-information/abstract-text/11487763 /pubmed\" target=\"_blank\" id=\"11487763 \">11487763 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Alora (estradiol transdermal system) [prescribing information]. Parsippany, NJ: Watson Pharma; November 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Drugs. &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/estradiol-systemic-pediatric-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson GL, Chlebowski RT, Aragaki AK, et al, &quot;Conjugated Equine Oestrogen and Breast Cancer Incidence and Mortality in Postmenopausal Women With Hysterectomy: Extended Follow-Up of the Women's Health Initiative Randomised Placebo-Controlled Trial,&quot; <i>Lancet Oncol,</i> 2012,13(5):476-86.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/estradiol-systemic-pediatric-drug-information/abstract-text/22401913/pubmed\" target=\"_blank\" id=\"22401913\">22401913</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ankarberg-Lindgren C, Elfving M, Wikland KA, Norjavaara E. Nocturnal application of transdermal estradiol patches produces levels of estradiol that mimic those seen at the onset of spontaneous puberty in girls. <i>J Clin Endocrinol Metab</i>. 2001;86(7):3039-3044.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/estradiol-systemic-pediatric-drug-information/abstract-text/11443165 /pubmed\" target=\"_blank\" id=\"11443165 \">11443165 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bannink EM, van Sassen C, van Buuren S, et al. Puberty induction in Turner syndrome: results of oestrogen treatment on development of secondary sexual characteristics, uterine dimensions and serum hormone levels. <i>Clin Endocrinol (Oxf)</i>. 2009;70(2):265-273.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/estradiol-systemic-pediatric-drug-information/abstract-text/19200215 /pubmed\" target=\"_blank\" id=\"19200215 \">19200215 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bondy CA, Turner Syndrome Study Group. Care of girls and women with Turner syndrome: a guideline of the Turner Syndrome Study Group. <i>J Clin Endocrinol Metab</i>. 2007;92(1):10-25.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/estradiol-systemic-pediatric-drug-information/abstract-text/17047017 /pubmed\" target=\"_blank\" id=\"17047017 \">17047017 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol - United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. Available at <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/estradiol-systemic-pediatric-drug-information/abstract-text/6810084 /pubmed\" target=\"_blank\" id=\"6810084 \">6810084 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chlebowski RT, Kuller LH, Prentice RL, et al, &quot;Breast Cancer After Use of Estrogen Plus Progestin in Postmenopausal Women,&quot; <i>N Engl J Med</i>, 2009, 360(6):573-87.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/estradiol-systemic-pediatric-drug-information/abstract-text/19196674/pubmed\" target=\"_blank\" id=\"19196674\">19196674</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Climara (estradiol transdermal system) [prescribing information]. Whippany, NJ: Bayer; October 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Davenport ML. Approach to the patient with Turner syndrome. <i>J Clin Endocrinol Metab</i>. 2010;95(4):1487-1495.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/estradiol-systemic-pediatric-drug-information/abstract-text/20375216 /pubmed\" target=\"_blank\" id=\"20375216 \">20375216 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Delestrogen (estradiol valerate) [prescribing information]. Rochester, MI: JHP Pharmaceuticals, LLC; October 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Depo-Estradiol (estradiol cypionate) [prescribing information]. New York, NY: Pharmacia &amp; Upjohn Company; October 2006.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DeSancho MT, Dorff T, and Rand JH, &quot;Thrombophilia and the Risk of Thromboembolic Events In Women on Oral Contraceptives and Hormone Replacement Therapy,&quot; <i>Blood Coagul Fibrinolysis</i>, 2010, 21(6):534-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/estradiol-systemic-pediatric-drug-information/abstract-text/20581664/pubmed\" target=\"_blank\" id=\"20581664\">20581664</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Divigel (estradiol gel) [prescribing information]. Maple Grove, MN: Upsher-Smith Laboratories; May 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Elestrin (estradiol gel) [prescribing information]. Philadelphia, PA: Azur Pharma; July 2010.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Estrace (estradiol) [prescribing information]. Rockaway, NJ: Warner Chilcott, LLC; April 2010.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Estrasorb (estradiol topical emulsion) [prescribing information]. Scottsdale, AZ: Medicis; December 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    EstroGel (estradiol gel) [prescribing information]. Herndon, VA: ASCEND Therapeutics; April 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Evamist (estradiol transdermal spray) [prescribing information]. Chesterfield, MO: Ther-Rx Corporation; July 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Femring (estradiol acetate) [prescribing information]. Rockaway, NJ: Warner Chilcott (US) LLC; May 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hindmarsh PC. How do you initiate oestrogen therapy in a girl who has not undergone puberty? <i>Clin Endocrinol (Oxf)</i>. 2009;71(1):7-10.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/estradiol-systemic-pediatric-drug-information/abstract-text/19226267 /pubmed\" target=\"_blank\" id=\"19226267 \">19226267 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Janfaza M, Sherman TI, Larmore KA, Brown-Dawson J, Klein KO. Estradiol levels and secretory dynamics in normal girls and boys as determined by an ultrasensitive bioassay: a 10 year experience. <i>J Pediatr Endocrinol Metab</i>. 2006;19(7):901-909.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/estradiol-systemic-pediatric-drug-information/abstract-text/16995570 /pubmed\" target=\"_blank\" id=\"16995570 \">16995570 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Menostar (estradiol transdermal system) [prescribing information]. Wayne, NJ: Bayer HealthCare; March 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Minivelle (estradiol transdermal system) [prescribing information]. Miami, FL: Noven Pharmaceuticals; September 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    M&oslash;rch LS, L&oslash;kkegaard E, Andreasen AH, et al, &ldquo;Hormone Therapy and Ovarian Cancer,&rdquo; <i>JAMA</i>, 2009, 302(3):298-305.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/estradiol-systemic-pediatric-drug-information/abstract-text/19602689/pubmed\" target=\"_blank\" id=\"19602689\">19602689</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    North American Menopause Society (NAMS). Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause. 2013 Sep;20(9):888-902.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/estradiol-systemic-pediatric-drug-information/abstract-text/23985562 /pubmed\" target=\"_blank\" id=\"23985562 \">23985562 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    North American Menopause Society (NAMS), &quot;The 2012 Hormone Therapy Position Statement of The North American Menopause Society,&quot; <i>Menopause</i>, 2012, 19(3):257-71.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/estradiol-systemic-pediatric-drug-information/abstract-text/22367731/pubmed\" target=\"_blank\" id=\"22367731\">22367731</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Palmert MR, Dunkel L. Clinical practice. Delayed puberty. <i>N Engl J Med</i>. 2012;366(5):443-453.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/estradiol-systemic-pediatric-drug-information/abstract-text/22296078 /pubmed\" target=\"_blank\" id=\"22296078 \">22296078 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Piippo S, Lenko H, Kainulainen P, Sipil&auml; I. Use of percutaneous estrogen gel for induction of puberty in girls with Turner syndrome. <i>J Clin Endocrinol Metab</i>. 2004;89(7):3241-3247.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/estradiol-systemic-pediatric-drug-information/abstract-text/15240598 /pubmed\" target=\"_blank\" id=\"15240598 \">15240598 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rosenfield RL, Devine N, Hunold JJ, Mauras N, Moshang T Jr, Root AW. Salutary effects of combining early very low-dose systemic estradiol with growth hormone therapy in girls with Turner syndrome. <i>J Clin Endocrinol Metab</i>. 2005;90(12):6424-6430.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/estradiol-systemic-pediatric-drug-information/abstract-text/16189255 /pubmed\" target=\"_blank\" id=\"16189255 \">16189255 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rossouw JE, Anderson GL, Prentice RL, et al, &quot;Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled Trial,&quot; <i>JAMA</i>, 2002, 288(3):321-33.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/estradiol-systemic-pediatric-drug-information/abstract-text/ 12117397 /pubmed\" target=\"_blank\" id=\" 12117397 \"> 12117397 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Santos XM. <i>Constitutional Delay of Puberty</i>.  In  Dietrich J.E.(ed.). <i>Female Puberty: A Comprehensive Guide for Clinicians</i>. New York: Springer Science+Business Media; 2014. </div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. <i>Pediatr Crit Care Med</i>. 2009;10(2):256-259.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/estradiol-systemic-pediatric-drug-information/abstract-text/19188870/pubmed\" target=\"_blank\" id=\"19188870\">19188870</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sperling MA, ed. <i>Pediatric Endocrinology</i>. 4th ed. Canada: Elsevier; 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    van Vlijmen EF, Veeger NJ, Middeldorp S, et al, &quot;Thrombotic Risk During Oral Contraceptive Use and Pregnancy in Women With Factor V Leiden or Prothrombin Mutation: A Rational Approach to Contraception,&quot; <i>Blood</i>, 2011, 118(8):2055-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/estradiol-systemic-pediatric-drug-information/abstract-text/21659542/pubmed\" target=\"_blank\" id=\"21659542\">21659542</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vivelle-Dot (estradiol transdermal system) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; May 2013.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 15980 Version 217.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F8018272\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F8018338\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F8018339\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F10824233\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F10824256\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F8018425\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F8018341\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F49280524\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F44524571\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F10824257\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49132514\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F12764945\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F10824238\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F8018336\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F8018353\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F8018348\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F8018349\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F26535327\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F8018356\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F8018357\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F8018361\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F8018343\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F8018344\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F10824261\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F27119868\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F8018378\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F8018385\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F8018427\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F11390228\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/15980|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=estradiol-systemic-drug-information\" class=\"drug drug_general\">Estradiol (systemic): Drug information</a></li><li><a href=\"topic.htm?path=estradiol-systemic-patient-drug-information\" class=\"drug drug_patient\">Estradiol (systemic): Patient drug information \t</a></li></ul></div></div>","javascript":null}